PHILOGEN SPA (PHIL.MI) Stock Price, Forecast & Analysis
BIT:PHIL • IT0005373789
PHIL.MI Key Statistics, Chart & Performance
The current stock price of PHIL.MI is 21.3 EUR. In the past year, price increased by 17.03%.
PHIL.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PHIL.MI. When comparing the yearly performance of all stocks, PHIL.MI turns out to be only a medium performer in the overall market: it outperformed 40.28% of all stocks.
PHIL.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to PHIL.MI. PHIL.MI is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
PHIL.MI Financial Highlights
Over the last trailing twelve months PHIL.MI reported a non-GAAP Earnings per Share(EPS) of 1.14. The EPS increased by 255.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 58.33% | ||
| ROA | 28.81% | ||
| ROE | 36.49% | ||
| Debt/Equity | 0.08 |
PHIL.MI Forecast & Estimates
8 analysts have analysed PHIL.MI and the average price target is 26.52 EUR. This implies a price increase of 24.51% is expected in the next year compared to the current price of 21.3.
For the next year, analysts expect an EPS growth of 14.73% and a revenue growth 112.03% for PHIL.MI
PHIL.MI Ownership
PHIL.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.35 | 44.705B | ||
| 1AE | ARGENX SE | 28.3 | 44.618B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.471B | ||
| ABVX | ABIVAX SA | N/A | 8.888B | ||
| 2X1 | ABIVAX SA | N/A | 8.872B | ||
| GLPG | GALAPAGOS NV | N/A | 1.891B | ||
| GXE | GALAPAGOS NV | N/A | 1.887B | ||
| IVA | INVENTIVA SA | N/A | 1.16B | ||
| 6IV | INVENTIVA SA | N/A | 1.112B | ||
| NANO | NANOBIOTIX | N/A | 1.055B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About PHIL.MI
Company Profile
Philogen SpA engages in the engineering and clinical development of lead products capable of targeting angiogenesis. The company is headquartered in Sovicille, Siena and currently employs 193 full-time employees. The company went IPO on 2021-03-03. The firm develops products and technologies for the diagnosis and therapy of serious human diseases. The company focuses mainly on discovering and developing targeted anti-cancer drugs, using high-affinity ligands for tumor markers. These ligands are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The Company’s products primarily address applications in the oncology field, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. The company has four anti-cancer antibody derivatives in clinical studies, one of which has completed a Phase III trial. The firm is active in the Discovery Unit through its subsidiary Philochem AG.
Company Info
PHILOGEN SPA
Via Bellaria, 35
Sovicille SIENA IT
Employees: 183
Phone: 39057717816
PHILOGEN SPA / PHIL.MI FAQ
What does PHIL do?
Philogen SpA engages in the engineering and clinical development of lead products capable of targeting angiogenesis. The company is headquartered in Sovicille, Siena and currently employs 193 full-time employees. The company went IPO on 2021-03-03. The firm develops products and technologies for the diagnosis and therapy of serious human diseases. The company focuses mainly on discovering and developing targeted anti-cancer drugs, using high-affinity ligands for tumor markers. These ligands are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The Company’s products primarily address applications in the oncology field, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. The company has four anti-cancer antibody derivatives in clinical studies, one of which has completed a Phase III trial. The firm is active in the Discovery Unit through its subsidiary Philochem AG.
What is the current price of PHIL stock?
The current stock price of PHIL.MI is 21.3 EUR.
What is the dividend status of PHILOGEN SPA?
PHIL.MI does not pay a dividend.
How is the ChartMill rating for PHILOGEN SPA?
PHIL.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for PHIL.MI stock?
8 analysts have analysed PHIL.MI and the average price target is 26.52 EUR. This implies a price increase of 24.51% is expected in the next year compared to the current price of 21.3.
What is the GICS sector and industry of PHIL stock?
PHILOGEN SPA (PHIL.MI) operates in the Health Care sector and the Biotechnology industry.
Would investing in PHILOGEN SPA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PHIL.MI.